Medivation Inc. (MDVN)
MDVN (NASDAQ:Drugs)
$48.51
+1.10
+2.32%
Today's Range: 47.35 - 49.00 |
MDVN Avg Daily Volume: 1,253,100
| Last Update: 05/21/13 - 4:00 PM EDT |
| Volume: 1,318,204 |
| YTD Performance: -7.10%
|
| Open: $47.59 |
| Previous Close: $47.41 |
| 52 Week Range: $39.62 -
$59.24 |
| Oustanding Shares: 74,976,902 |
| Market Cap: 3,563,652,152 |
6-Month Chart
TheStreet Ratings Grade for MDVN
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
9 |
8 |
8 |
8 |
| Moderate Buy |
1 |
1 |
1 |
0 |
| Hold |
3 |
3 |
3 |
3 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.54 |
1.58 |
1.58 |
1.55 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
12/31/69 |
| Price Earnings Ratio: |
-51.11 |
|
| Price Earnings Comparisons: |
| MDVN |
Sector Avg. |
S&P 500 |
| -51.11 |
0.00 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
-7.13%
|
14.20%
|
802.75%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
200.90 |
1.62 |
0.37 |
| Net Income |
0.00 |
-0.25 |
0.00 |
| EPS |
0.00 |
-0.35 |
0.00 |
| Earnings for MDVN: |
| EBITDA |
-0.03B |
| Revenue |
0.18B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$-0.23 |
$-0.26 |
$-1.07 |
$0.48 |
| Number of Analysts |
11 |
12 |
10 |
11 |
| High Estimate |
$-0.13 |
$-0.05 |
$-0.86 |
$1.41 |
| Low Estimate |
$-0.44 |
$-0.42 |
$-1.40 |
$-0.43 |
| Prior Year |
$-0.08 |
$-0.06 |
$-0.56 |
$-1.07 |
| Growth Rate (Year over Year) |
-210.30% |
-326.39% |
-90.71% |
144.77% |
Mar 04, 2013 | 7:09 AM EST
MDVN was initiated with a Buy rating, Needham said. Xtandi is rapidly gaiing market share for the treatment of prostate cancer.
...
Dec 19, 2012 | 8:44 AM EST
MDVN was initiated with a Neutral rating, UBS said. $59 price target. Xtandi should drive conversion to profitability, but peak expecta...
Nov 12, 2012 | 8:09 AM EST
Shares of MDVN now seen reaching $62, Jefferies said. Estimates also raised on Xtandi beat. Buy rating.
By
Adam Feuerstein and Gregg Greenberg
Oct 26, 2012 | 5:00 AM EDT
Adam Feuerstein, Sr. Columnist for TheStreet, says biotech earnings are the next big things to watch in biotech.
Oct 03, 2012 | 7:35 AM EDT
Shares of MDVN now seen reaching $70, Citigroup said. Estimates also increased to reflect higher Xtandi US price. Buy rating.
| Sep 04, 2012 | 10:48 AM EDT
Motivated CEOs, innovative products and smart deals count more than macro events.
Sep 04, 2012 | 7:58 AM EDT
Shares of MDVN now seen reaching $122, Jefferies said. Estimates also raised on Xtandi approval. Buy rating.
Sep 04, 2012 | 7:27 AM EDT
Shares of MDVN now seen reaching $149, according to Credit Suisse. Estimates also increased, given the earlier-than-expected approval o...
Aug 10, 2012 | 7:54 AM EDT
Shares of MDVN now seen reaching $120, according to Credit Suisse. Estimates also reduced, given rising operating costs. Outperform rat...
| Jul 03, 2012 | 12:04 PM EDT
These mid-caps are volatile, but a merger or major announcement could send them soaring.
